ClinicalTrials.gg
Not yet recruitingNCT07726914Updated Nov 13, 2026

Study to Compare the Plasma Concentration of Belumosudil Given as an Oral Suspension and as a Tablet to Healthy Adult Male Participants

A Phase 1 interventional study of Belumosudil and Belumosudil in Chronic Graft Versus Host Disease, sponsored by Sanofi. Not yet recruiting. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Updated Nov 13, 2026Eligibility revisedStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome — 7 open to participants now, 8 under way, 2 of them phase 3. belumosudil · Bronchiolitis Obliterans Syndrome.

Planned enrollment
5th of 14
58 · median 34
Started
2026
with 3 others
Phase 1
2 of 14
2 open now
Registered
13th of 14
by date
Lead sponsor
6 of 14
Sanofi

Among the 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome, this one is the 5th largest by planned enrollment, is one of 4 that started in 2026, is one of 2 in phase 1, and was the 13th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

7 of the 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About belumosudil

belumosudil: first FDA approval 2021 (REZUROCK), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome, or all of them as a file.
02

Study summary

The purpose of this open-label, randomized, cross-over, Phase 1, 2-treatment, 2-period, 2-sequence study is to assess the bioequivalence of belumosudil oral suspension compared with belumosudil tablet in healthy male participants aged 18 to 45 years, inclusive.

Study details include:

The study duration will be approximately 40 days. The treatment period will be up to 8 days. At least 3 days post-treatment follow-up period. end of study: 6±1 days from the last dose. The number of visits will be 3.

03

Conditions studied

  • Chronic Graft Versus Host Disease
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy male participant between 18 to 45 years of age, inclusive
  • Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
  • Participants with normal renal function ( ≥90 mL/min) at Screening and Day-1.
  • Body weight between 50.0 and 115.0 kg, inclusive, and between 18.0 and 32.0 kg/m2, inclusive
  • use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  • Capable of giving signed

Exclusion Criteria, participants are excluded from the study if any of the following criteria apply:

  • Any history or presence of cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness
  • Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).
  • Blood donation (usually approximately 500 mL) within 2 months before inclusion
  • Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in SBP ≥30 mmHg within 3 minutes when changing from supine to standing position
  • Presence or history of drug , or allergic disease diagnosed and treated by a physician. Participants with known hypersensitivity to any component of the IMP formulation or allergic disease diagnosed and treated by a physician
  • History or current presence of drug or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis). Medically prescribed cannabis is not allowed
  • Smoking regularly more than 5 cigarettes or equivalent in nicotine per week, unable to stop smoking (occasional smoker can be enrolled)
  • Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day)
  • Clinically significant history or presence of acute or chronic bacterial, fungal, or viral infection (eg, pneumonia, septicaemia) within the 3 months or 90 days prior to screening
  • Known or suspected , disorder, or any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status or any factor that would predispose participants to develop infection (eg, open skin lesion, recurrent issue related to poor dentition, perianal fissures, history of splenectomy, primary immunodeficiency)
  • Any medication (including proton pump inhibitors, inducers or strong and moderate CYP3A inhibitors, St John's Wort, or ginseng) within 14 days before study treatment administration or 5 half-lives, whichever is longer
  • Use of any herbal medicines within 2 weeks before each IMP administration and up to the end of PK sampling following the IMP administration
  • Any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion
  • Current enrollment OR past participation in another study in which an investigational intervention (eg, drug, vaccine, invasive device) was administered within the last 90 days or 5 half-lives whichever is longer, before inclusion in this clinical study
  • Positive result on any of the following tests: HBs Ag, Ab (total or IgM), anti- antibodies, anti- 1 and 2 antibodies
  • Confirmed positive result on urine drug screen (amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, opiates)
  • Confirmed positive alcohol breath test
  • Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    belumosudil tablet,then belumosudil oral suspension

    belumosudil tablet in period 1, then belumosudil oral suspension in period 2.

    Drug: Belumosudil

  • Experimental
    belumosudil oral suspension, then belumosudil tablet

    belumosudil oral suspension in period 1, then belumosudil tablet in period 2.

    Drug: Belumosudil

Interventions

  • Pharmaceutical form:Tablet-Route of administration:Oral

    Also known as: SAR445761, REZUROCK

  • Pharmaceutical form:Oral suspension-Route of administration:Oral

    Also known as: SAR445761, REZUROCK

06

What researchers measure

Primary outcomes

  1. AUClast

    Area under the plasma concentration versus time curve until the time of last quantifiable concentration

    Time frame: Baseline (H0) to Day 3 (H48) for each of the 2 periods

  2. Cmax

    Maximum plasma concentration observed

    Time frame: Baseline (H0) to Day 3 (H48) for each of the 2 periods

Secondary outcomes

  1. tmax

    Time to reach Cmax

    Time frame: Baseline (H0) to Day 3 (H48) for each of the 2 periods

  2. t1/2z

    Terminal half-life associated with the terminal slope (λz)

    Time frame: Baseline (H0) to Day 3 (H48) for each of the 2 periods

  3. tlag

    Interval between administration time and the sampling time preceding the first concentration above the limit of quantification

    Time frame: Baseline (H0) to Day 3 (H48) for each of the 2 periods

  4. AUC

    Area under the plasma concentration versus time curve extrapolated to infinity

    Time frame: Baseline (H0) to Day 3 (H48) for each of the 2 periods

  5. AUClast/AUC

    AUClast/AUC ratio

    Time frame: Baseline (H0) to Day 3 (H48) for each of the 2 periods

  6. λz

    slope of the regression line of the observed terminal phase of the concentration versus time curve

    Time frame: Baseline (H0) to Day 3 (H48) for each of the 2 periods

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2027, 2 months later.

Of 22 phase 1 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 2 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Aug 2026 → Nov 2026, primary completion Sep 2026 → Jan 2027 and completion Sep 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Jul 24, 2026
StartEst.
Nov 17, 2026was Aug 2026
Primary completionEst.
Jan 26, 2027was Sep 2026
CompletionEst.
Jan 26, 2027was Sep 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 6, 2026→Nov 17, 2026
Nov 10, 2026
Primary completion
Sep 28, 2026→Jan 26, 2027
Nov 10, 2026
Study completion
Sep 28, 2026→Jan 26, 2027
Nov 10, 2026
Eligibility
1 criterion added
What changed in the criteria
  • AddedParticipants with normal renal function (GFR ≥90 mL/min) at Screening and Day-1.
Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    Eligibility 1 criterion added
    What changed in the criteria
    • AddedParticipants with normal renal function (GFR ≥90 mL/min) at Screening and Day-1.
  2. Nov 10, 2026
    Start date Aug 6, 2026→Nov 17, 2026
    Primary completion Sep 28, 2026→Jan 26, 2027
    Study completion Sep 28, 2026→Jan 26, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07726914
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jul 24, 2026
Start date
Nov 17, 2026 (estimated)
Primary completion
Jan 26, 2027 (estimated)
Completion
Jan 26, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion